Cancer Immunology, Immunotherapy

, Volume 55, Issue 11, pp 1320–1329 | Cite as

Expression of macrophage-derived chemokine (MDC)/CCL22 in human lung cancer

  • Toru Nakanishi
  • Kazuyoshi Imaizumi
  • Yoshinori HasegawaEmail author
  • Tsutomu Kawabe
  • Naozumi Hashimoto
  • Masakazu Okamoto
  • Kaoru Shimokata
Original Article


Background: Ligands for CXCR3 chemokines [IFN-γ-inducible protein of 10 kD (IP-10/CXCL10), monokine induced by IFN-γ (Mig/CXCL9), IFN-inducible T cell α chemoattractant (I-TAC/CXCL11)] and those for CCR4 [macrophage-derived chemokine (MDC/CCL22), thymus- and activation-regulated chemokine (TARC/CCL17)] have been shown to play the central roles for T helper-cell recruitment into the tissues. To examine the role of these chemokines in tumor progression of lung cancer, we investigated their expression in human lung cancer tissues to determine the possible relationship between their expression and the prognosis of patients. Methods: Total RNA was prepared from lung cancer tissues of 40 patients (24 adenocarcinoma and 16 squamous cell carcinoma). We measured gene expression levels of chemokines (IP-10, Mig, I-TAC, MDC and TARC) by real-time quantitative RT-PCR. Results: Higher gene expression of MDC in lung cancer was significantly correlated with longer disease-free survival time and lower risk of recurrence after tumor resection. We could not find any significant relationship of IP-10, Mig, I-TAC and TARC gene expression with disease-free survival or lower risk of recurrence after surgery. Conclusions: These results suggest that increased gene expression of MDC in tumor tissues may be a predictive marker for improving the prognosis of lung cancer.


Lung cancer Macrophage-derived chemokine (CCL22) Prognosis Real-time quantitative RT-PCR 



Macrophage-derived chemokine


Interferon-inducible protein of 10 kD


Monokine induced by interferon-gamma


Interferon-inducible T cell α chemoattractant


Thymus- and activation-regulated chemokine


Reverse transcription-polymerase chain reaction


Tumor necrosis factor-α


Interferon γ


Glyceraldehyde-3-phosphate dehydrogenase



The authors thank Ms. Ayako Asai, Emi Kusama, Hiromi Isejima and Keiko Shimamoto for their continuous technical assistance. This work was supported in part by a Grant-in-Aid for the 21st Century COE Program “Integrated Molecular Medicine for Neuronal and Neoplastic Disorders” from the Ministry of Education, Culture, Sports, Science and Technology and a Grant-in-Aid for the Scientific Research from the Japan Society for the Promotion of Science.


  1. 1.
    Winterhalder RC, Hirsch FR, Kotantoulas GK, Franklin WA, Bunn PA Jr (2004) Chemoprevention of lung cancer—from biology to clinical reality. Ann Oncol 15:185–196PubMedCrossRefGoogle Scholar
  2. 2.
    Rea F, Marulli G, Callegaro D, Zuin A, Gobbi T, Loy M, Sartori F (2004) Prognostic significance of main bronchial lymph nodes involvement in non-small cell lung carcinoma: N1 or N2? Lung Cancer 45:215–220PubMedCrossRefGoogle Scholar
  3. 3.
    Frederick MJ, Clayman GL (2001) Chemokines in cancer. Expert Rev Mol Med 2001:1–18Google Scholar
  4. 4.
    Arya M, Patel HRH, Williamson M (2003) Chemokines: key players in cancer. Curr Med Res Opin 19:557–564PubMedCrossRefGoogle Scholar
  5. 5.
    Van Damme J, Struyf S, Opdenakker G (2004) Chemokine-protease interactions in cancer. Semin Cancer Biol 14:201–208PubMedCrossRefGoogle Scholar
  6. 6.
    Opdennakker G, van Damme J (2004) The countercurrent principle in invasion and metastasis of cancer cells. recent insights on the roles of chemokines. Int J Dev Biol 48:519–527CrossRefGoogle Scholar
  7. 7.
    D’Ambrosio D, Mariani M, Panina-Bordignon P, Sinigaglia F (2001) Chemokines and their receptors guiding T lymphocyte recruitment in lung inflammation. Am J Respir Crit Care Med 164:1266–1275PubMedGoogle Scholar
  8. 8.
    Sauty A, Dziejman M, Taha RA, Iarossi AS, Neote K, Garcia-Zepeda EA, Hamid Q, Luster AD (1999) The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells. J Immunol 162:3549–3558PubMedGoogle Scholar
  9. 9.
    Qiu B, Frait KA, Reich F, Komuniecki E, Chensue SW (2001) Chemokine expression dynamics in mycobacterial (type-1) and schistosomal (type-2) antigen-elicited pulmonary granuloma formation. Am J Pathol 158:1503–1515PubMedGoogle Scholar
  10. 10.
    Carlo ED, Cappello P, Sorrentino C, D’Antuono T, Pellicciotta A, Giovarelli M, Forni G, Musiani P, Triebel F (2005) Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway. J Pathol 205:82–91PubMedCrossRefGoogle Scholar
  11. 11.
    Sekiya T, Miyamasu M, Imanishi M, Yamada H, Nakajima T, Yamaguchi M, Fujisawa T, Pawankar R, Sano Y, Ohta K, Ishii A, Morita Y, Yamamoto K, Matsushima K, Yoshie O, Hirai K (2000) Inducible expression of a Th2-type CC chemokine thymus- and activation-regulated chemokine by human bronchial epithelial cells. J Immunol 165:2205–2213PubMedGoogle Scholar
  12. 12.
    Ikeda H, Chamoto K, Tsuji T, Suzuki Y, Wakita D, Takeshima T, Nishimura T (2004) The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci 95:697–703PubMedCrossRefGoogle Scholar
  13. 13.
    Noguchi M, Imaizumi K, Kawabe T, Wakayama H, Horio Y, Sekido Y, Hara T, Hashimoto N, Takahashi M, Shimokata K, Hasegawa Y, (2001) Induction of antitumor immunity by transduction of CD40 ligand gene and interferon-gamma gene into lung cancer. Cancer Gene Ther 8:421–429PubMedCrossRefGoogle Scholar
  14. 14.
    White ES, Flaherty KR, Carskadon S, Brant A, Iannettoni MD, Yee J, Orringer MB, Arenberg DA (2003) Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res 9:853–860PubMedGoogle Scholar
  15. 15.
    Monti P, Leone BE, Marchesi F, Balzano G, Zerbi A, Scaltrini F, Pasquali C, Calori G, Pessi F, Sperti C, Di Carlo V, Allavena P, Piemonti L (2003) The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. Cancer Res 63:7451–7461PubMedGoogle Scholar
  16. 16.
    Burger M, Glodek A, Hartmann T, Schmitt-Graff A, Silberstein LE, Fujii N, Kipps TJ, Burger JA (2003) Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene 22:8093–8101PubMedCrossRefGoogle Scholar
  17. 17.
    Tepper RI, Pattengale PK, Leder P (1989) Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57:503–512PubMedCrossRefGoogle Scholar
  18. 18.
    Nagai S, Toi M (2000) Interleukin-4 and breast cancer. Breast Cancer 7:181–186PubMedCrossRefGoogle Scholar
  19. 19.
    Guo J, Wang B, Zhang M, Chen T, Yu Y, Regulier E, Homann HE, Qin Z, Ju DW, Cao X (2002) Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity. Gene Ther 9:793–803PubMedCrossRefGoogle Scholar
  20. 20.
    Lee JM, Merritt RE, Mahtabifard A, Yamada R, Kikuchi T, Crystal RG, Korst RJ (2003) Intratumoral expression of macrophage-derived chemokine induces CD4+ T cell-independent antitumor immunity in mice. J Immunother 26:117–129PubMedCrossRefGoogle Scholar
  21. 21.
    Ghia P, Transidico P, Veiga JP, Schaniel C, Sallusto F, Matsushima K, Sallan SE, Rolink AG, Mantovani A, Nadler LM, Cardoso AA (2001) Chemoattractants MDC and TARC are secreted by malignant B-cell precursors following CD40 ligation and support the migration of leukemia-specific T cells. Blood 98:533–540PubMedCrossRefGoogle Scholar
  22. 22.
    Marx J (2004) Inflammation and cancer: the link grows stronger. Science 306:966–968PubMedCrossRefGoogle Scholar
  23. 23.
    Lin EY, Nguyen AV, Russell GR, Pollard JW (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193:727–740PubMedCrossRefGoogle Scholar
  24. 24.
    Daniel D, Meyer-Morse N, Bergsland EK, Dehne K, Coussens LM, Hanahan D (2003) Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med 197:1017–1028PubMedCrossRefGoogle Scholar
  25. 25.
    Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, Burdick MD, Glass MC, Taub DT, Iannettoni MD, Whyte RI, Strieter RM (1996) Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 184:981–992PubMedCrossRefGoogle Scholar
  26. 26.
    Kondo T, Ito F, Nakazawa H, Horita S, Osaka Y, Toma H (2004) High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma.. J Urol 171:2171–2175PubMedCrossRefGoogle Scholar
  27. 27.
    Okada N, Gao JQ, Sasaki A, Niwa M, Okada Y, Nakayama T, Yoshie O, Mizuguchi H, Hayakawa T, Fujita T, Yamamoto A, Tsutsumi Y, Mayumi T, Nakagawa S (2004) Anti-tumor activity of chemokine is affected by both kinds of tumors and the activation state of the host’s immune system: implications for chemokine-based cancer immunotherapy. Biochem Biophys Res Commun 317:68–76PubMedCrossRefGoogle Scholar
  28. 28.
    Berin MC, Eckmann L, Broide DH, Kagnoff MF (2001) Regulated production of the T helper 2-type T-cell chemoattractant TARC by human bronchial epithelial cells in vitro and in human lung xenografts. Am J Respir Cell Mol Biol 24:382–389PubMedGoogle Scholar
  29. 29.
    Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949PubMedCrossRefGoogle Scholar
  30. 30.
    Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351–360PubMedCrossRefGoogle Scholar
  31. 31.
    Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N (2004) A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350:1713–1721PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Toru Nakanishi
    • 1
  • Kazuyoshi Imaizumi
    • 1
  • Yoshinori Hasegawa
    • 1
    Email author
  • Tsutomu Kawabe
    • 2
  • Naozumi Hashimoto
    • 1
  • Masakazu Okamoto
    • 1
  • Kaoru Shimokata
    • 1
  1. 1.Department of Respiratory Medicine Nagoya University Graduate School of MedicineNagoyaJapan
  2. 2.Department of Medical TechnologyNagoya University Graduate School of Health ScienceNagoyaJapan

Personalised recommendations